CREXONT
Growthcarbidopa and levodopa
NDAORALCAPSULE, EXTENDED RELEASE
Approved
Aug 2024
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
1
Mechanism of Action
DOPA Decarboxylase Inhibitors
Pharmacologic Class:
Aromatic Amino Acid Decarboxylation Inhibitor
Clinical Trials (1)
Effect of BIA 9-1067 at Steady-state on the Pharmacokinetics of Levodopa/Carbidopa and Levodopa/Benserazide
Started Mar 2009
Loss of Exclusivity
LOE Date
Dec 21, 2041
192 months away
Patent Expiry
Dec 21, 2041
Exclusivity Expiry
Aug 7, 2027